EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · IEX Real-Time Price · USD
8.01
-0.30 (-3.61%)
At close: Jul 2, 2024, 4:00 PM
8.02
+0.01 (0.12%)
After-hours: Jul 2, 2024, 7:47 PM EDT
EyePoint Pharmaceuticals Employees
EyePoint Pharmaceuticals had 121 employees as of December 31, 2023. The number of employees decreased by 23 or -15.97% compared to the previous year.
Employees
121
Change (1Y)
-23
Growth (1Y)
-15.97%
Revenue / Employee
$413,380
Profits / Employee
-$652,190
Market Cap
417.20M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 121 | -23 | -15.97% |
Dec 31, 2022 | 144 | 21 | 17.07% |
Dec 31, 2021 | 123 | 22 | 21.78% |
Dec 31, 2020 | 101 | 17 | 20.24% |
Dec 31, 2019 | 84 | 40 | 90.91% |
Dec 31, 2018 | 44 | 22 | 100.00% |
Jun 30, 2017 | 22 | 2 | 10.00% |
Jun 30, 2016 | 20 | -6 | -23.08% |
Jun 30, 2015 | 26 | 2 | 8.33% |
Jun 30, 2014 | 24 | -1 | -4.00% |
Jun 30, 2013 | 25 | -4 | -13.79% |
Jun 30, 2012 | 29 | 3 | 11.54% |
Jun 30, 2011 | 26 | 3 | 13.04% |
Jun 30, 2010 | 23 | 1 | 4.55% |
Jun 30, 2009 | 22 | 1 | 4.76% |
Jun 30, 2008 | 21 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
EYPT News
- 14 days ago - EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 - GlobeNewsWire
- 15 days ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 2 months ago - EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal - Market Watch
- 2 months ago - EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy - GlobeNewsWire
- 3 months ago - EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists - GlobeNewsWire
- 4 months ago - EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire